shutterstock_1871127568_rafapress

rafapress / Shutterstock.com

7 November 2023Big PharmaMarisa Woutersen

Court partially grants disqualification of PacBio’s legal team

Genomics company’s in-house attorney removed from case over links with patent infringement case | Court denied plaintiff’s motion to disqualify entire legal team.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Personal Genomics takes PacBio dispute to Chinese court

22 May 2020 Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More on this story

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Personal Genomics takes PacBio dispute to Chinese court

22 May 2020 Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More on this story

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Personal Genomics takes PacBio dispute to Chinese court

22 May 2020 Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims